Immunization with 60kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 67-75

  Kurien, B T ^a,b,c   Dsouza, A ^a,b,c   Igoe, A ^a,b   Lee, Y J ^a,d   Maier Moore, J S ^a,b,c   Gordon, T ^e   Jackson, M ^e   Scofield, R H ^a,b,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Seoul National University Bundang Hospital   (South Korea)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Animal models studies mice rats; Anti SSA(Ro) SSB(La) antibodies; Autoimmunity; Genetics; Sjogren's syndrome

Indexed keywords

MUSCARINIC M3 RECEPTOR; PEPTIDE; RO PEPTIDE; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CARBACHOL; EPITOPE; FREUND ADJUVANT; H2 ANTIGEN; PEPTIDE FRAGMENT; RIBONUCLEOPROTEIN; SMALL CYTOPLASMIC RNA; SS A ANTIBODIES; SS B ANTIGEN; SS-A ANTIBODIES; SS-B ANTIGEN; SSA2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; GENETIC REGULATION; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; SALIVATION; SJOEGREN SYNDROME; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; BLADDER; DISEASE MODEL; DRUG EFFECT; GENETICS; GERMFREE ANIMAL; HAPLOTYPE; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; MOLECULAR GENETICS; MOUSE STRAIN; PATHOLOGY; PRODROMAL SYMPTOM; SALIVARY GLAND; SMOOTH MUSCLE; XEROSTOMIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; AUTOIMMUNITY; CARBACHOL; DISEASE MODELS, ANIMAL; EPITOPES; FREUND'S ADJUVANT; H-2 ANTIGENS; HAPLOTYPES; IMMUNIZATION; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH; PEPTIDE FRAGMENTS; PRODROMAL SYMPTOMS; RECEPTOR, MUSCARINIC M3; RIBONUCLEOPROTEINS; RNA, SMALL CYTOPLASMIC; SALIVARY GLANDS; SALIVATION; SJOGREN'S SYNDROME; SPECIFIC PATHOGEN-FREE ORGANISMS; URINARY BLADDER; XEROSTOMIA;

MLCS; MLOWN;

EID: 84878799374     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12094     Document Type: Article

References (42)

1. Scofield RH. Rapid review: autoantibodies as predictors of disease. Lancet 2004; 363:1544-1546.
2. Rose NR. Predictors of autoimmune disease: autoantibodies and beyond. Autoimmunity 2008; 41:419-428.
3. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011; 3:131-138.
4. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010; 32:468-478.
5. Tzioufas AG, Voulgarelis M. Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007; 21:989-1010.
6. Vitali C, Bombardieri S, Jonsson R etal. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. European Study Group on Classification Criteria for Sjogren's Syndrome. Ann Rheum Dis 2002; 61:554-558.
7. Vitali C. Measurement of disease activity and damage in Sjogren's syndrome. Rheum Dis Clin North Am 2008; 34:963-971.
8. Lawrence RC, Felson DT, Helmick CG etal., National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26-35.
9. Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjogren's syndrome. Eur J Clin Invest 2010; 40:1026-1036.
10. Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med 2009; 265:653-662.
11. McCune AB, Weston WL, Lee LA. Maternal and fetal outcome in neonatal lupus erythematosus. Ann Intern Med 1987; 106:518-523.
12. Julkunen H, Eronen M. Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44:647-652.
13. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544-551.
14. Delaleu N, Nguyen CQ, Peck AB, Jonsson R. Sjögren's syndrome: studying the disease in mice [Review]. Arthritis Res Ther 2011; 13:217-233.
15. Robinson CP, Brayer J, Yamachika S etal. Transfer of human serum IgG to nonobese diabetic Igμnull mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc Natl Acad Sci USA 1998; 95:7538-7543.
16. Fujita H, Fujihara T, Takeuchi T, Saito I, Tsubota K. Lacrimation and salivation are not related to lymphocytic infiltration in lacrimal and salivary glands in MRL lpr/lpr mice. Adv Exp Med Biol 1998; 438:941-948.
17. Kimura T, Suzuki K, Inada S etal. Induction of autoimmune disease by graft-versus-host reaction across MBC class II difference: modification of the lesions in IL-6 transgenic mice. Clin Exp Immunol 1994; 95:525-529.
18. Koike K, Moriya K, Ishibashi K etal. Sialadenitis histologically resembling Sjögren's syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 1997; 94:233-236.
19. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice. J Immunol 1994; 153:2769-2777.
20. Tsubata R, Tsubata T, Hiai H etal. Autoimmune disease of exocrine organs in immunodeficient alymphoplasia mice: a spontaneous model for Sjögren's syndrome. Eur J Immunol 1996; 26:2742-2748.
21. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum 2002; 46:1390-1398.
22. Fleck M, Kern ER, Zhou T, Lang B, Mountz JD. Murine cytomegalovirus induces a Sjögren's syndrome-like disease in C57Bl/6-lpr/lpr mice. Arthritis Rheum 1998; 41:2175-2184.
23. Fleck M, Zhang HG, Kern ER, Hsu HC, Müller-Ladner U, Mountz JD. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum 2001; 44:964-973.
24. Ohyama Y, Carroll VA, Deshmukh U, Gaskin F, Brown MG, Fu SM. Severe focal sialadenitis and dacryoadenitis in NZM2328 mice induced by MCMV: a novel model for human Sjogren's syndrome. J Immunol 2006; 177:7391-7397.
25. Scofield RH, James JA. Immunization as a model for systemic lupus erythematosus. Semin Arthritis Rheum 1999; 29:140-147.
26. Mamula MJ. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 1998; 164:231-239.
27. Scofield RH, Asfa S, Obeso D, Jonsson R, Kurien BT. Immunization with short peptides from the 60kD Ro/SSA antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjögren's syndrome. J Immunol 2005; 175:8409-8414.
28. Scofield RH, Kaufman KM, Baber U etal. Immunization of mice with human 60kD Ro peptides results in epitope spreading if the peptides are highly homologous between man and mouse. Arthritis Rheum 1999; 42:1017-1024.
29. Scofield RH, Pierce PG, James JA, Kaufman KM, Kurien BT. Immunization with peptides from 60kDa Ro in diverse mouse strains. Scand J Immunol 2002; 56:477-483.
30. Scofield RH, Kurien BT, Zhang F etal. Protein-protein interaction of the Ro-ribonucleoprotein particle using multiple antigenic peptides. Mol Immunol 1999; 36:1093-1106.
31. Kurien BT, Jackson K, Scofield RH. Immunoblotting of multiple antigenic peptides. Electrophoresis 1998; 19:1659-1661.
32. Scofield RH, Henry WE, Kurien BT, James JA, Harley JB. Immunization with short peptides from the sequence of the systemic lupus erythematosus-associated 60-kDa Ro autoantigen results in anti-Ro ribonucleoprotein autoimmunity. J Immunol 1996; 156:4059-4066.
33. Wang F, Jackson MW, Maughan V etal. Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 2004; 50:3637-3645.
34. Park K, Haberberger RV, Gordon TP, Jackson MW. Antibodies interfering with the muscarinic 3 receptor pathway in Sjogren's syndrome inhibit gastrointestinal motility and cholinergic neurotransmission. Arthritis Rheum 2011; 63:1426-1434.
35. Nguyen KH, Brayer J, Cha S etal. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43:2297-2306.
36. Yin H, Vosters JL, Roescher N etal. Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren's syndrome. PLoS ONE 2011; 6:e18003.
37. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? Arthritis Rheum 2005; 52:2984-2995.
38. Nandula RS, Scindia Y, Bagavant H, Deshmukh U. Activation of innate immunity leads to accelerated development of Sjogren's syndrome-like disorder in NZB/W F1 mice. Arthritis Rheum 2009; 60 (Suppl. 10):1960.
39. Nguyen C, Limaye N, Wakeland EK. Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res 2002; 4:S255-263.
40. Jennings P, Chan A, Schwartzberg P, Wakeland EK, Yuan D. Antigen-specific responses and ANA production in B6.Sle1b mice: a role for SAP. J Autoimmun 2008; 31:345-353.
41. Li QZ, Zhou J, Yang R etal. The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun 2009; 10:503-508.
42. Liu K, Li QZ, Yu Y etal. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun 2007; 8:634-645.